In the midst of this, pharmaceutical, biotechnology and medical device companies operating internationally are increasingly embroiled in complex multijurisdictional patent litigation. At the same time, increasing pricing pressure is forcing them to lay claim to new and complex branding initiatives as they bid to keep hold or increase their market shares. Added to these are the markets for counterfeit drugs and medical devices that threaten consumer and brand health.
Pharmaceutical companies are also coming to terms with an environment in which generics are on the rise. Money is being poured into research and development, but compulsory licensing and expiring patents mean that work has to be made more efficient and cost effective. Most importantly, new drugs need to get to market more quickly without compromising patient safety.
Meanwhile, new life sciences technology is on the rise, forcing attorneys to find new ways of drafting patent applications so that the broadest amount of coverage is provided unopposed. New clusters of investors, universities, private labs and dedicated legal boutiques are emerging too, ensuring that the needs of new technology are serviced at every level as efficiently and well as possible.
As this complex sector develops and heads in new directions, IPPro Life Sciences will be there to report on these and other major advances, as well as all of the latest news from around the world.
From private practice life sciences groups, to multinational pharmaceutical companies, university labs and venture capitalists, IPPro Life Sciences has something for everyone with an interest in intellectual property and the legal implications for the life sciences sector.